Metabolic Disease Overview

Principles

Definition

Metabolic disease is an academic concept and research domain focused on the study of disorders involving abnormal biochemical processes, such as those related to energy production, nutrient utilization, and waste product handling. This field investigates the etiology, pathophysiology, diagnosis, and treatment of a diverse array of conditions resulting from these metabolic derangements, which represent a major area of biomedical research and public health concern.

Ontological type

Pathophysiological Mechanisms

Therapeutic Strategies

Etiology and Risk Factors

Key developments

Key Figures

Genetic-Enzymatic Paradigm era

Scott M. Grundy [1], active within the genetic-enzymatic diagnostic paradigm of 1963–1980, is associated with Rockefeller University [3] and the Massachusetts Institute of Technology [4] during this era. His 1975 study Effects of obesity and caloric intake on biliary lipid metabolism in man [7] highlighted enzymatic and metabolic variation as targets for diagnosis and population screening, shaping metabolic-disease paradigms of the era. Robert Schwartz [2], whose career traversed Harvard University [5] and Stanford University [6], contributed to the genetic-enzymatic framework central to metabolic disorders in this period. His 1966 monograph Disorders of Carbohydrate Metabolism in Infancy [8] aided early newborn screening and genotype-to-phenotype diagnostic concepts, reinforcing the enzymology-centered approach of the era.

Pathway-Driven Clinical Translation era

Paul Zimmet [1] is a leading figure in the Pathway-Driven Clinical Translation era of metabolic disease, with affiliations at Johns Hopkins University [3] and the University of Washington [4]. His key contribution in this era was helping define the metabolic syndrome as a worldwide diagnostic framework, The metabolic syndrome—a new worldwide definition [7], catalyzing standardized screening and management approaches. Gerald I. Shulman [2] is associated with Rockefeller University [5] and Harvard University [6], and his key contribution in this era includes work on mitochondrial dysfunction and insulin resistance as described in Mitochondrial Dysfunction in the Elderly: Possible Role in Insulin Resistance [8]. These contributions collectively anchored the era's pathway-driven clinical translation by linking mitochondrial energy metabolism to diagnostic criteria and management strategies.

Systems Biomarker Risk Synthesis era

Vincent Wai‐Sun Wong [1] is associated with Harvard University [3] and Stanford University [4] during the Systems Biomarker Risk Synthesis era (2009–2024). His key contributions in this era derive from the MASLD clinical practice guidelines [6], the global burden of metabolic disease data [7], and the redefinition's epidemiological impact on MASLD [8], which collectively advanced biomarker-informed risk stratification and policy guidance. Cisca Wijmenga [2] has affiliations with TiFN [5] and Harvard University [3] in this era. Her notable contribution is the 2019 paper causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases [9], which underscores microbiome–host metabolic signaling as a driver of cardiometabolic risk in systems biomarker synthesis.